サンプル依頼リスト カート
  • English
  • Korean
表紙：がんケアにおけるゲノミクスの世界市場-2023年～2030年
市場調査レポート
商品コード
1297793

がんケアにおけるゲノミクスの世界市場-2023年～2030年

Global Genomics in Cancer Care Market - 2023-2030

出版日
ページ情報
英文 195 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
がんケアにおけるゲノミクスの世界市場-2023年～2030年
出版日: 2023年06月15日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

市場概要

がんケアにおけるゲノミクスの世界市場は、2022年に134億米ドルに達し、2030年には511億米ドルに達するなど、有利な成長が予測されています。がんケアにおけるゲノミクスの世界市場は、2023年から2030年の予測期間中に18.9%のCAGRを示すと予測されています。

がん細胞における特定の分子標的の同定は、ゲノム解析によって支援されます。標的療法は、これらの標的の活性化を特異的に阻害または阻止することで、健康な細胞を温存しながらがん細胞を破壊することができます。例えば、HER2陽性乳がんのHER2タンパク質を標的とするトラスツズマブや、慢性骨髄性白血病のBCR-ABL融合タンパク質を標的とするイマチニブのような薬剤です。

診断、個別化医療、創薬・市場開拓における応用の拡大が、がんケアにおけるゲノミクス市場の成長を牽引しています。がん罹患率の上昇、疾患の早期診断に関する意識の高まり、高齢者人口の増加、技術の進歩などの要因が市場成長を後押ししています。

市場力学

ゲノムシークエンシングの進歩が予測期間中のがんケアにおけるゲノミクス世界市場の成長を後押し

DNAシーケンシングと腫瘍の塩基レベルでのゲノム解析において、疾患の新たな分子的原因が発見され、がん生物学に対する理解が一変し、より効果的な治療と患者の転帰改善の道が開かれました。

バルク組織から単一細胞まで、ショートリード、ハイスループット、ロングリードの1分子およびナノポアシーケンス法の現在および将来の最先端を網羅する幅広いシーケンスプラットフォームや、極めて低インプットのライブラリー調製法のための新規分子アプローチ、DNAおよびRNAプロファイリング用途の両方における関心遺伝子の標的化、および増幅フリーのCas9ベースの濃縮戦略などが、この技術の一例です。

リキッドバイオプシーの採用が、予測期間中のがんケアにおけるゲノミクス世界市場の成長を後押しする

がんを特定し治療するための最も効果的なアプローチは、生検による腫瘍組織の採取です。米国国立がん研究所によると、最先端の治療薬が増加する中、肺がんは世界で最も死亡率の高い悪性腫瘍の1つであり、年間15万人以上の命が奪われる可能性が高いです。

過去10年間におけるリキッドバイオプシー・プラットフォームの開発における技術革新により、血液ベースの検査に対する規制当局の承認数が増加しているため、進行がん患者に対する精密がん医療は変化しつつあります。

個別化医療の拡大が世界のがんケアにおけるゲノミクス市場に成長機会をもたらす

FDAによると、個別化医療と標的療法は医薬品開発における実質的な進歩であり、腫瘍学は腫瘍の種類によっては最も急速に成長している治療分野の1つです。標的療法と免疫療法は、個別化医療ががんの治療で頻繁に使用する2種類の医薬品です。

COVID-19影響分析

COVID-19の流行はがんケアにおけるゲノミクス市場に大きな影響を与えています。COVID-19の調査とワクチンの開発は、研究機関や資金提供元から大きな注目を集めました。このため、がんケアにおけるゲノミクスなど、COVIDとは無関係の研究イニシアチブに遅延や資金制限が生じた可能性があります。このことは、新しい治療法や診断ツールの開発、進行中のゲノム研究の進展に影響を与えるかもしれないです。

ロシア・ウクライナ紛争分析

ロシア・ウクライナ紛争ががん医療市場におけるゲノム研究に与える影響は複雑で多面的です。紛争により、ヘルスケアや研究プロジェクト、特にがんケアにおけるゲノミクスに関わるプロジェクトのための資源や資金が流用されました。

ヘルスケア・インフラや研究への投資は政府の優先順位を下げ、紛争の当面の影響に対処する方向に向かったが、これはゲノミクス技術の開発と導入に影響を与える可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • がんの負担増
    • 抑制要因
      • ゲノミクス機器に関連する高価格
    • 機会
      • 個別化医療の拡大
    • 影響分析

第5章 産業分析

  • ポーターの5フォース分析
  • サプライチェーン分析
  • アンメットニーズ
  • 規制分析

第6章 COVID-19分析

第7章 ロシア・ウクライナ戦争分析

第8章 人工知能分析

第9章 製品別

  • 機器
  • 消耗品
  • サービス

第10章 技術別

  • ゲノムシーケンス
  • PCR法
  • マイクロアレイ
  • 核酸抽出・精製
  • その他

第11章 用途別

  • 診断
  • 個別化医療
  • 創薬・医薬品開発
  • 調査

第12章 エンドユーザー別

  • 病院
  • 研究機関
  • 学術機関
  • その他

第13章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第14章 競合情勢

  • 競合シナリオ
  • 製品ベンチマーク
  • 企業シェア分析
  • 主な発展と戦略

第15章 企業プロファイル

  • Roche Diagnostics
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • AstraZeneca PLC
  • Illumina, Inc
  • Affymetrix
  • Agilent Technologies
  • Cancer Genetics Inc.
  • Beckman Coulter Inc.
  • Bio-Rad Labs
  • Danaher Corporation
  • Sigma Aldrich Corporation（Merck KGaA）

第16章 付録

目次
Product Code: BT3410

Market Overview

The Global Genomics In Cancer Care Market reached US$ 13.4 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 51.1 billion by 2030. The Global Genomics In Cancer Care Market is expected to exhibit a CAGR of 18.9% during the forecast period 2023-2030.

The identification of specific molecular targets in cancer cells is aided by genomic analysis. Targeted therapies can destroy cancer cells while sparing healthy cells by specifically inhibiting or preventing the activation of these targets. For instance, drugs like trastuzumab, which targets the HER2 protein in HER2-positive breast cancer, and imatinib, which targets the BCR-ABL fusion protein in chronic myeloid leukemia.

The increasing application in diagnostics, personalized medicine, and drug discovery & development drives the genomics in cancer care market growth. Factors such as rising cancer incidence, increasing awareness about early disease diagnosis, growing geriatric population, and technological advancement drive market growth.

Market Dynamics

The Advancement in Genome Sequencing is Boosting the Global Genomics in Cancer Care Market Growth During the Forecast Period

In DNA sequencing and genomic analysis of tumors at the nucleotide level, new molecular causes of the disease have been discovered, revolutionizing our understanding of cancer biology and paving the way for more effective treatments and better patient outcomes.

A wide range of sequencing platforms, covering the present and future state of the art for short-read, high-throughput, and long-read single molecule and nanopore sequencing methods from bulk tissue to single cells, as well as novel molecular approaches for extremely low-input library preparation methods, targeting genes of interest in both DNA and RNA profiling applications, as well as amplification-free Cas9-based enrichment strategies, are among the technologies.

The Adoption of Liquid Biopsies is Boosting the Global Genomics in Cancer Care Market Growth During the Forecast Period

The most effective approach for identifying and treating cancer is the collection of tumor tissue through biopsies. According to the National Cancer Institute, with an increasing number of cutting-edge medications, lung cancer is one of the deadliest malignancies in the world and will likely claim the lives of over 150,000 people annually.

Precision cancer care for patients with advanced disease is changing due to innovations in the development of liquid biopsy platforms during the past ten years, which have resulted in an increasing number of regulatory approvals for blood-based testing.

The Expansion of Personalized Medicine Provides Global Genomics in Cancer Care Market Growth Opportunities

According to the FDA, personalized medicine and targeted therapies represent a substantial advancement in drug development, and oncology is one of the therapeutic fields that is growing the fastest for some types of tumors. Targeted therapies and immunotherapies are the two types of medicines that personalized medicine frequently uses in the treatment of cancer.

COVID-19 Impact Analysis

The COVID-19 pandemic has significantly impacted Genomics In The Cancer Care Market. The research on COVID-19 and the creation of a vaccine received significant attention from research institutions and funding sources. This may have caused delays or funding restrictions for research initiatives unrelated to COVID, such as genetics in cancer treatment. This might affect the development of novel treatments or diagnostic tools and the advancement of ongoing genomic studies.

Russia-Ukraine Conflict Analysis

The impact of the Russia-Ukraine war on genomics in the cancer care market is complex and multifaceted. Resources and financing for healthcare and research projects, especially those involving genetics in cancer treatment, were diverted due to the conflict.

Investments in healthcare infrastructure and research reduced government priorities and moved towards managing the immediate effects of the conflict, which could have an impact on the development and uptake of genomics technology.

Segment Analysis

The Global Genomics In Cancer Care Market is segmented based on product, technology, application, End User and region.

The Genome Sequencing Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period

The genome sequencing segment accounted for the highest market stake, accounting for approximately 36.4% of the genomics in the cancer care market in 2022. Genome sequencing can be done using various techniques and technologies, and technological improvements have made it possible to sequence genomes more quickly, accurately, and affordably.

Next-generation sequencing (NGS) technologies have transformed genome sequencing. Compared to Sanger sequencing, NGS platforms can produce enormous amounts of sequencing data in parallel, enabling high-throughput sequencing. Different strategies, such as sequencing by synthesis or ligation, are used by NGS techniques, such as Illumina sequencing, to ascertain the DNA sequence.

Geographical Analysis

Increasing Collaborations and Partnerships Among the Key Players, Increasing FDA Approvals, and Advancement in Genomics in Cancer Care Dominate the North American Region

North America is expected to dominate the genomics in the cancer care market, accounting for around 39.9%. The market players are applying market strategies such as product launches and collaboration to expand their business. For instance, in January 2023, Arima Genomics, Inc. announced a partnership with Protean BioDiagnostics, to make a next-generation sequencing (NGS)-based test from Arima available to doctors for patient management in the United States.

Competitive Landscape

The major global players in the market include: Roche Diagnostics, AstraZeneca PLC, Illumina, Inc., Affymetrix, Agilent Technologies, Cancer Genetics Inc., Beckman Coulter Inc., Bio-Rad Labs, Danaher Corporation, and Sigma Aldrich Corporation (Merck KGaA) (Merck KGaA) among others.

Why Purchase the Report?

  • To visualize the Global Genomics In Cancer Care Market segmentation based on the product, technology, application, End User, and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of genomics at the cancer care market level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The Global Genomics In Cancer Care Market Report Would Provide Approximately 69 Tables, 69 Figures And 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product
  • 3.2. Snippet by Technology
  • 3.3. Snippet by Application
  • 3.4. Snippet by End User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The growing burden of cancer
    • 4.1.2. Restraints
      • 4.1.2.1. High price associated with genomics devices
    • 4.1.3. Opportunity
      • 4.1.3.1. The expansion of personalized medicine
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Analysis

9. By Product

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 9.1.2. Market Attractiveness Index, By Product
  • 9.2. Instruments*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Consumables
  • 9.4. Services

10. By Technology

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.1.2. Market Attractiveness Index, By Technology
  • 10.2. Genome Sequencing*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. PCR
  • 10.4. Microarray
  • 10.5. Nucleic Acid Extraction and Purification
  • 10.6. Others

11. By Application

    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.1.2. Market Attractiveness Index, By Application
  • 11.2. Diagnostics*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Personalized Medicine
  • 11.4. Drug Discovery & Development
  • 11.5. Research

12. By End User

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 12.1.2. Market Attractiveness Index, By End User
  • 12.2. Hospitals*
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 12.3. Research Institutes
  • 12.4. Academic Institutes
  • 12.5. Others

13. By Region

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 13.1.2. Market Attractiveness Index, By Region
  • 13.2. North America
    • 13.2.1. Introduction
    • 13.2.2. Key Region-Specific Dynamics
    • 13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.2.7.1. The U.S.
      • 13.2.7.2. Canada
      • 13.2.7.3. Mexico
  • 13.3. Europe
    • 13.3.1. Introduction
    • 13.3.2. Key Region-Specific Dynamics
    • 13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.3.7.1. Germany
      • 13.3.7.2. The U.K.
      • 13.3.7.3. France
      • 13.3.7.4. Italy
      • 13.3.7.5. Spain
      • 13.3.7.6. Rest of Europe
  • 13.4. South America
    • 13.4.1. Introduction
    • 13.4.2. Key Region-Specific Dynamics
    • 13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.4.7.1. Brazil
      • 13.4.7.2. Argentina
      • 13.4.7.3. Rest of South America
  • 13.5. Asia-Pacific
    • 13.5.1. Introduction
    • 13.5.2. Key Region-Specific Dynamics
    • 13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.5.7.1. China
      • 13.5.7.2. India
      • 13.5.7.3. Japan
      • 13.5.7.4. Australia
      • 13.5.7.5. Rest of Asia-Pacific
  • 13.6. Middle East and Africa
    • 13.6.1. Introduction
    • 13.6.2. Key Region-Specific Dynamics
    • 13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

14. Competitive Landscape

  • 14.1. Competitive Scenario
  • 14.2. Product Benchmarking
  • 14.3. Company Share Analysis
  • 14.4. Key Developments and Strategies

15. Company Profiles

  • 15.1. Roche Diagnostics*
    • 15.1.1. Company Overview
    • 15.1.2. Product Portfolio and Description
    • 15.1.3. Financial Overview
    • 15.1.4. Key Developments
  • 15.2. AstraZeneca PLC
  • 15.3. Illumina, Inc
  • 15.4. Affymetrix
  • 15.5. Agilent Technologies
  • 15.6. Cancer Genetics Inc.
  • 15.7. Beckman Coulter Inc.
  • 15.8. Bio-Rad Labs
  • 15.9. Danaher Corporation
  • 15.10. Sigma Aldrich Corporation (Merck KGaA)

LIST NOT EXHAUSTIVE

16. Appendix

  • 16.1. About Us and Services
  • 16.2. Contact Us